

CURRICULUM VITAE

Jack Thomas Stapleton, M.D.

Personal Data

Dept. of Internal Medicine & Microbiology
SW54, GH UIHC
200 Hawkins Drive
Iowa City, IA 52242
319-356-3168 (phone)
Citizenship: USA

Education

1973-1975	(Biology)	Drake University, Des Moines, Iowa
1975-1977	A.B.	University of Iowa, Iowa City, Iowa
1977-1980	M.D.	University of Kansas Kansas City, Kansas
1980-1983	Resident	Internal Medicine University of N Carolina, Chapel Hill, NC
1983-1984	Fellow	Microbiology University of N Carolina, Chapel Hill, NC
1984-1986	Fellow and Clinical Instructor	Infectious Diseases University of N Carolina, Chapel Hill, NC

Academic Appointment

1986-1987	Instructor	University of Iowa
1987-1991	Assistant Professor	University of Iowa
1987-present	Staff Physician	Iowa City VA Medical Center
1988-1992	Research Associate	Veterans Administration
1988-present	Director, Virology (HIV/AIDS) Clinic	University of Iowa Hospitals and Clinics
1991-1996	Associate Professor (tenure)	University of Iowa
1996-present	Professor, Dept. of Internal Medicine	University of Iowa
1999-2000	Advanced Career Enhancement Award	Veterans Admin.
1999-present	Director, Helen C. Levitt Center for Viral Pathogenesis and Disease	University of Iowa
2004-present	Faculty, Interdisciplinary Program in Molecular Biology	University of Iowa
2004 – 2010	Director, Division of Infectious Diseases	University of Iowa
2004 – present	Director, Division of Infectious Diseases, Iowa City VA	
2011-present	Professor, Microbiology and Immunology Dept.	Univ. Iowa

Certification

American Board of Internal Medicine	1983	091225
ABIM, Infectious Diseases Subspecialty Boards	1986	091225
AHIVMA HIV Certification: 2005, 2007, 2009, 2011, 2013, 2016		11510

Licensure

North Carolina	25833
Iowa	25543

Professional Affiliations

Alpha Omega Alpha, American College of Physicians (Fellow), American Society of Microbiology, Infectious Disease Society of America (Fellow), American Society for the Study of Liver Diseases, Central Society for Clinical Research, HIV Medicine Association, American Academy of HIV Medicine, Association of American Physicians, American Clinical and Climatological Association

Honors and Awards

1974 Phi Eta Sigma Honor Society, Drake University
1980 Alpha Omega Alpha Honor Fraternity
1980 Mahlon Delp Award (Senior Medical Student Award
Department of Internal Medicine, Kansas University)
1984 Individual National Research Service Award
(1 F32 AI06988-01) National Institutes of Health
1988 Research Associate Award, Veterans Administration
1989 Midwest AFCR-Upjohn Excellence in Research in
Infectious Diseases Award
1991, '96, '09 Nominee, M4 Teacher of the Year
1992 Elected: Central Society of Clinical Research
1994 Fellow, Infectious Diseases Society of America
1996 Fellow, American College of Physicians
1998-2003 Infectious Diseases Research Advisory Committee, VA (Chair, 2000-2003)
1999 Advanced Career Development Award, Veterans Administration
1999-present Director, Helen C. Levitt Center for Viral Pathogenesis
2002-2007 Virology-Immunology Advisory Committee, Community Program for
Clinical Research on AIDS.
2003-present Hepatitis Working Group. Multicenter AIDS Cohort Study.
2003-2006 Safety Monitoring Committee (Chair): NIH-DMID Anthrax vaccine studies
2005 NIH Review Panel, Hepatitis C Center Grants
2005 Review Panel, Middleton Award, Dept. of Veterans Affairs
2005 NIH AIDS and Opportunistic Infection Complications Study Section -Ad hoc
2006 VA Career Development Study Section
2006-present Elected: Association of American Physicians
2006-present Editorial Advisory Board, *Journal of Infectious Diseases*
2006 Stonewall Award, Iowa City GLBT organization
2006-2010 Member, U.S. FDA Vaccines and Related Biological Products Advisory
Committee
2007-present "America's Top Physicians", Consumers' Research Council of America
2007-present Editorial Board, *Retrovirology: Research and Treatment*
2007 NIH Virology B Study Section (Temporary Member)
2010 Chair, FDA Vaccines and Related Biological Products Advisory Committee
2010-2013 Member, VA Infectious Diseases Merit Grant Review Panel (Chair 2012-13)
2012-present Member, Flavivirus Study Group. International Committee on the
Taxonomy of Viruses
2012 Member, NIH Special Emphasis Study Section on HIV Vaccine Centers
2012-present Elected: American Clinical and Climatological Association
2013-2014 Ad hoc member NIAID T32 – MID Study Section
2014-pres Standing member, NIAID T32 – MID Study Section
2016-pres Member, U.S. FDA Blood Products Advisory Committee

Areas of Research Interest

- 1.) Flavivirus interactions with human immune cells
- 2.) Flavivirus (HCV, GBV-C, YFV) interactions with HIV
- 3.) Antiviral therapy, vaccine and OI clinical trials.

Current Projects

Flavivirus replication, entry and interactions with T cells and NK cells *in vitro* and *in vivo*.
Flavivirus – HIV interactions *in vitro* and *in vivo*. Longitudinal study of HCV and GBV-C in HIV cohorts (MACS, WIHS, WITS, ALIVE, HPTN, and VACS). Several Antiviral (HIV, HCV) and Vaccine (HPV, influenza, MVA, Yellow Fever virus, etc.) clinical trials

Review Activity:

Recent Advisory Boards - Consultation: Food and Drug Administration (FDA) Blood Products Advisory Committee (2016-2020), FDA Vaccines and Related Biological Products Advisory Committee (2006-2010, Chair 2010); Journal of Infectious Diseases Editorial Advisory Board (2008 – present); Retrovirology: Research and Treatment Editorial Advisory Board (2008-present); Multicenter AIDS Cohort Study (MACS): Hepatitis Working Group (2004 – present); NIAID, DMID Safety Monitoring Committee Chair (for 5 vaccine studies); External consultant for American Association of Blood Banks Transfusion Transmitted Diseases Committee. Liver Action Plan (HIV-HCV co-infection - primary reviewer, NIDDK).

Review Activity: Ad Hoc Grants and Contracts

VA Merit Review; UIHC Clinical Research Center; Ontario HIV Network; Health Research Board's Research Project Grants, 2004. Wellcome Trust, 2004, 2005. Site visitor for Laboratory of mycobacterial diseases and cellular immunology, FDA, May, 2007. Chair, site visitor for Laboratory of Virus Diseases, FDA/CBER, April, 2008. Chair, site visitor for Laboratory of Vector Borne Virus Diseases/Hepatitis Viruses, April, 2010; Wellcome Trust (2010); Pennsylvania Interim Performance Review (2011); Pasteur Institute (2012).

Review Activity: Miscellaneous NIH and VA Study Sections

NHBLI Special Emphasis Grant Review Committee HCV Center Grants, 2000. VA AIDS Centers Review Committee (2000; Chair). VA Infectious Diseases Career Development Award Study Section (chair 2000-2003). NIH Special Emphasis Review Panel on Hepatitis C Virus Cooperative Center Grants, 2005. VA Middleton Award review committee, 2005, VA Career Development Study Section (2006). NIAID Study Section "Virology B" (ad hoc, 2007). VA Merit Review Panel A (2010-2013). Annual Biomedical Research Conference for Minority Students Poster Reviewer (2011). NIH Special Emphasis Review Panel (HIV Vaccine Center grants; 2012), NIAID MID-A T-32 Study Section (ad hoc, 2013, 2014; standing member 2014 - 2020).

Ad Hoc Reviewer - Journals

Nature Biotechnol; Science Translational Medicine; PLoS Pathogens; Scientific Reports (Nature publishing); J Virology; Proceedings of the National Academy of Sciences; Cell Host and Microbe; J Clinical Investigation; mBio; Virology; Annals of Internal Medicine; Hepatology; Journal of the American Medical Association; Virology Journal; Journal of Medical Virology; American Journal of Medicine; Journal of Infectious Diseases; Journal of Acquired Immune Deficiency Syndromes; Journal of Immunology; Clinical Infectious Diseases; Epidemiology and Infection; Vaccine; Journal of Clinical Microbiology; Gastroenterology; Archives of Internal Medicine; American Journal of Gastroenterology; Antiviral Therapy; FEBS Letters; AIDS; Veterinary Microbiology, BioMed Central; Gut Online; European Journal of Clinical Investigation; American Journal of Clinical Nutrition, FEBS Journal; Journal of General Virology; Virus Research; American Journal of Tropical Medicine; Int J Cancer, Trans RSocTropMedHyg; J Infect; Blood; PLoS One; Clinica Chmica Acta; Eur J Clin Invest; Chem Biol Drug Des; Diag Microbiol Infect Dis; Virol J;

Revista do Instituto de Medicina Tropical de São Paulo; AIDS and Human Retroviruses; Archives of Virology; Colloids and Surfaces B: HIV Research and Treatment; Biointerfaces; Expert Reviews of Anti-Infective Therapy; J Med Chem; Nephrology Reviews; J Clin Immunol, J Leukocyte Biology.

Current Mentoring

Amber Ford	Thesis Committee, Department of Microbiology
Jacklyn Johnson	Thesis Committee, Department of Microbiology
Ashley Cooney	Thesis Committee, Department of Microbiology
Jennifer Welch	Thesis Committee, Department of Microbiology

Invited Presentations (since 2008)

1. Co-Chair, War and Peace Between Microbes: Co-Pathogens as Determinants of HIV. Symposium. XVII International AIDS Society Meeting. Mexico City, Mexico. August 4, 2008.
2. Mechanisms of GBV-C interference with HIV replication in vivo and in vitro. XVII International AIDS Society Meeting. Mexico City, Mexico. August 4, 2008.
3. Co-pathogenic factors influencing HIV disease progression. Royal Infectious Disease Unit, University of Edinburgh. August 29, 2008.
4. How a nonpathogenic virus influences HIV Disease Progression: GBV-C interactions with T cells. National Institute of Childhood Diseases, November 19, 2009.
5. GBV-C influences HIV disease progression via antiviral and lymphocyte modulation mechanisms. Chicago Developmental Center for AIDS Research. Rush University, August 20, 2010.
6. "The Role and Influence of Advisory Bodies on the US Market for Pandemic Influenza Vaccine". Center for Infectious Diseases Research and Policy (CIDRAP) 2nd Comprehensive Influenza Vaccine Initiative working group. Alexandria, VA. September 15-16, 2010.
7. Effects of GBV-C infection on T cell activation. Oral Presentation, Conference on Retroviruses and Opportunistic Infections. Boston, MA, Feb. 26, 2011.
8. GBV-C infection reduces B cell and NK cell activation markers and monocyte CCR5 surface expression. Oral Presentation. International AIDS Society Conference, Rome, Italy, July 20, 2011.
9. IDSA HIVMA Press Conference, GBV-C E2 protein inhibits HIV replication. Boston, MA, October 21, 2011.
10. GBV-C effects on TCR signaling. Rush University, December 18, 2012.
11. GBV-C inhibits T cell activation modifying HIV Disease progression, Seminars in Basic and Clinical Investigation, San Antonio VA and UTHSC San Antonio, Texas, April 2, 2013.
12. GBV-C: A risk for NonHodgkin's Lymphoma? Special Seminar, National Cancer Institute, NIH. June 13, 2013.
13. GB virus C and HIV: Interactions and Outcomes. Infectious Diseases Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, September 5, 2013..
14. GB virus C and HIV: Interactions and Outcomes. Global Infectious Diseases Seminar, Wisconsin National Primate Research Center, Madison, WI, September 6, 2013.
15. A novel mechanism used by RNA viruses to evade T cell immune responses. American Clinical and Climatological Meeting. October 18, 2013.
16. A novel T cell evasion mechanisms in persistent RNA virus infection. Allergy-Immunology Grand Rounds, University of Iowa. November 6, 2013.

17. Non-hepatitis hepatitis viruses. Viral hepatitis Grand Rounds. University of Pennsylvania. June 4, 2014.
18. Flavivirus envelop proteins inhibit T cell receptor signaling. Microbiology Seminar, E. Carolina University, Greenville, NC. September 18, 2014.
19. Novel mechanisms of immune evasion by Flaviviruses. Biomedical Sciences Seminar Series, Iowa State University Veterinary School, April 2, 2015.
20. HIV and HCV update for the Primary Care Physician. 17th Annual Update in Infectious Diseases. Iowa City, April 17, 2015.
21. Viral coinfection: GB C virus and HIV. NIH/NIDDK ApoL1 and Kidney Disease Conference. College Park, MD. June 3, 2015
22. Novel, virus-derived short RNA mechanism regulates T cell receptor signaling. Special Seminar; Burnet Institute, Melbourne, Australia. March 3, 2016.
23. Identification of new mechanisms used by RNA viruses to modulate T cell activation. University of North Carolina Institute for Global Health and Infectious Diseases. Chapel Hill,NC. May 13, 2017
24. HCV genome derived small RNA regulates a Src-kinase regulatory phosphatase in human liver and PBMCs and reduces T cell activation. HCV 2016, Kyoto Japan, October 14, 2016.

Current Financial Resources

VA Merit Review-Basic Science: The effects of hepatitis C virus (HCV) E2 protein on host immunomodulation (PI JTS)	2017-2021
NIH T32: Infectious Diseases Training Grant (PI-JTS)	2004-2020
Ryan White Part C: HIV Service Delivery in Rural Iowa (PI JTS)	1998-2018
Ryan White Part B: Case Management (PI JTS) renewed annually	2003-2018
NIH/DMID: Vaccine Treatment and Evaluation Unit (VTEU) (PI Winokur; Stapleton is Associate Director)	2007-2021
NIH R01: The effect of HIV and cocaine abuse on semen exosome composition and function (PI Okeoma, Role: Co-Inv)	2016-2021

Personnel/Trainees

Current Clinical Personnel:

Colleen Brem, M.S.N., A.R.N.P.	Nurse Practitioner (10%)	1998
Tricia Kroll, M.S.W.	Social Worker	1998
Kathryn Flanders, ARNP	Study Coordinator	2005
Rina Chaudhary, Ph.D.	Program Coordinator	2008
Wendy Sauter, MSN	Clinic Nurse	2010
Jennifer Keeler, BSW	Social Worker	2011
Katie Vodraska, BSW	Social Worker	2015
Sarah Hambright, BSW	Social Worker	2015
Michael Bates	Data Manager	2015
Nina Pliakos	Nursing Assistant	2015
Robin Hayward, PA-C	Physicians Assistant	2017

Current Laboratory Personnel:

Donna Klinzman	Research Technician III	1991
Jinhua Xiang, M.D., M.M.	Assoc. Research Scientist	1996
Qing Chang	Research Asst. II	2000
James McLinden, Ph.D.	Assoc. Research Scientist	2002
Tom Kaufman	Senior Research Technician,	2003

BIBLIOGRAPHY

1. **Stapleton JT**, Gillman MW. Hypoglycemic coma due to norpace toxicity. *S Med J* 76:1453, 1983.
2. **Stapleton JT**, Stamm LV, Bassford PJ. The potential for development of antibiotic resistance in pathogenic treponemes. *Rev Infect Dis* 7:S314-317, 1985.
3. **Stapleton JT**, Jansen R, Lemon SM. Serum neutralizing antibody to hepatitis A virus in immune serum globulin and in the sera of human recipients of immune serum globulin. *Gastroenterology* 88:1427-1432, 1985.
4. **Stapleton J**, Lemon SM. Transmission of hepatitis B while monitoring blood glucose. (Letter) *JAMA*, 253:3250, 1985.
5. **Stapleton JT**, Lemon SM. Delta hepatitis, a recently recognized entity. *Diagnosis* 7:26-35, 1985.
6. **Stapleton JT**, Lemon SM. Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. *J Virol* 61:491-498, 1987.
7. **Stapleton JT**, Lemon SM. New insights into hepatitis A vaccine development. *Infect Med* 4:330-337, 1987.
8. Schwalbe RS, **Stapleton JT**, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. *N Engl J Med* 316:927-931, 1987.
9. Schwalbe RS, **Stapleton JT**, Gilligan PH. Vancomycin resistance in coagulase-negative staphylococcus. *N Engl J Med* 317:766-767, 1987. (letter)
10. **Stapleton J**, Britz J, Carlson JR, Folds J. A patient with AIDS and a false negative HIV Western blot. *Infect Control* 8:490-491, 1987.
11. **Stapleton JT**, Lange DK. Trypsin sensitivity of epitopes within the Hepatitis A virus immunodominant neutralization site. In: *Vaccines 88*, Ginsberg H, Brown F, Lerner RA, Chanock R (eds), Cold Spring Harbor Press, New York, 1988, pp. 235-240, 1988.
12. Ping LH, Jansen RW, **Stapleton JT**, Murphy PC, Cohen JI, Lemon SM. An immunodominant neutralization site residing on capsid protein VP3 of human hepatitis A virus. *UCLA Symp Mol Cell Biol N Sec* 84:527-537, 1988.
13. Lemon SM, **Stapleton JT**, LeDuc JW, Taylor D, Marchwicki R, Binn LN: A cell culture-adapted variant of hepatitis A virus selected for resistance to neutralizing monoclonal antibody retains virulence in owl monkeys. In: *Viral Hepatitis*, Zuckerman AJ, ed. Alan R. Liss, New York, 1988, pp. 70-74.
14. Stamm LV, **Stapleton JT**, Bassford PJ. *In vitro* assay to demonstrate high-level erythromycin resistance of a clinical isolate of *treponema pallidum*. *Antimicrob Agents Chemother* 32:164-169, 1988.
15. Mertz GJ, Jones CC, Mills J, Fife K, Lemon SM, **Stapleton JT**, Davis LG, Hill J, and the Acyclovir Study Group: Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection: a multicenter double-blind trial. *JAMA* 260:201-206, 1988.
16. Shamsuddin H, **Stapleton JT**. HIV Infection: Clinical manifestations, therapy and transmission. *Iowa Medicine* 78:125-128, 1988.
17. Kaplan AH, Poza-Juncal E, Shepiro R, **Stapleton JT**. Cure of mucormycosis in a renal transplant recipient receiving maintenance ciclosporin with maintenance of immunosuppression. *Am J Nephrol* 8:139-142, 1988.
18. Ping LH, Jansen RW, **Stapleton JT**, Cohen JI, Lemon SM. Identification of an immunodominant antigenic site involving capsid protein VP3 of hepatitis A virus. *Proc Natl Acad Sci USA* 85:8281-8285, 1988.

19. **Stapleton JT**, Lemon SM. Hepatitis A. In: Infectious Diseases, A Modern Treatise of Infectious Process, P.D. Hoepflich and M.C. Jordan (Eds.), 4th Edition, J.B. Lippincott Company, Philadelphia, Chapter 78, pp. 758-766, 1989.
20. Balfour HH, Chase BN, **Stapleton JT**, Simmons RL, Fryd DS. Acyclovir prevents cytomegalovirus disease in renal allograft recipients. *N Eng J Med* 320:1381-1387, 1989.
21. **Stapleton JT**. HIV transmission, health care workers, and media hype. (Editorial). *Infect Control Hosp Epidemiol* 10:503-504, 1989.
22. Lemon SM, Binn LN, Marchwicki R, Murphy P, Ping L, Jansen RW, Asher LVS, **Stapleton JT**, Taylor D, LeDuc JW. *In vivo* replication and reversion to wild type of a neutralization-resistant antigenic variant of hepatitis A virus. *J Infect Dis* 161:7-13, 1990.
23. Veach L, **Stapleton JT**. Mechanical ventilation for pneumocystis carinii pneumonia in AIDS. *Chest* 97:1499-1500, 1990.
24. Cox E, Emerson S, Lemon S, Ping L, **Stapleton J**, Guiler M, Feinstone S. Use of oligonucleotide directed mutagenesis to define the immunodominant neutralization antigenic site of hepatitis A virus. In: Vaccines 90, H. Ginsberg, F. Brown, R.A. Lerner, and R. Chanock (Eds.), Cold Spring Harbor Press, p. 169-173, 1990.
25. **Stapleton JT**, Lange DK, LeDuc JW, Binn LN, Jansen R, Lemon SM: The role of secretory immunity in Hepatitis A virus infection. *J Infect Dis* 163:7-11, 1991.
26. Hughes D, **Stapleton J**. Postoperative toxic shock syndrome. *Iowa Medicine* 81:55-58, 1991.
27. **Stapleton JT**, Rosen E, McLinden J. Detection of hepatitis A virus capsid proteins in insect cells infected with recombinant baculoviruses encoding the entire HAV open reading frame. In: Viral Hepatitis and Liver Disease, Hollinger, F.B. ed. Williams & Wilkins, p. 50-54, 1991.
28. Day S, Lemon S, Sharpe D, **Stapleton JT**, Cox E, Feinstone S, Stein L. Evaluation of the human B lymphocyte response to hepatitis A virus (HAV). In: Viral Hepatitis and Liver Disease, Hollinger, F.B. ed. Williams & Wilkins, p. 69-70, 1991.
29. Ferguson KJ, **Stapleton JT**, Helms CM. Physicians' effectiveness in assessing risk for HIV infection. *Arch Intern Med* 151:561-564, 1991.
30. McLinden J, Rosen E, **Stapleton JT**. Anti-HAV neutralizing antibodies made to antigens produced by recombinant baculoviruses. In: Vaccines 91: Modern Approaches to New Vaccines, Cold Spring Harbor Press, p. 239-244, 1991.
31. Densen P, **Stapleton J**. Is the AIDS epidemic ending? *Iowa Medicine* 81:167-169, 1991.
32. **Stapleton JT**. Book Review of Textbook of Human Virology, Robert B. Belshe (ed.). *Infect Control Hosp Epidemiol* 12:391-392. 1991.
33. Winokur PL, McLinden J, **Stapleton JT**. The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into virus-like particles. *J Virol* 65:5029-5036, 1991.
34. Davis KA, **Stapleton J**. Migration to rural areas by HIV patients: Impact on HIV related health care delivery. *Infect Control Hosp Epidemiol* 12:540-544, 1991.
35. **Stapleton JT**, Frederick J, Meyer B. Hepatitis A virus attachment to cultured cell lines. *J Infect Dis* 164:1098-1103, 1991.
36. **Stapleton JT**. Viral Hepatitis. *Medical and Health Annual*. Encyclopaedia Britannica, Inc., p.342-347, 1992.
37. Winokur PL, **Stapleton JT**. Immunoglobulin prophylaxis of Hepatitis A virus. *Clin Infect Dis* 14:580-586, 1992.

56. Schutt DC, **Stapleton JT**, Kennedy RC, Soll DR. HIV-induced syncytia in peripheral blood cell cultures crawl by extending giant pseudopods. *Cell Immunol* 166:261-274, 1995.
57. **Stapleton JT**, Lemon SM. New vaccines against hepatitis A. In: New Generation Vaccines, M.R. Levine, G.C.Woodrow, J.B. Kaper, G.S.Cobon, eds. Second Edition, Marcel Dekker, Inc. New York, pp 571-585, 1997.
58. Han J-Q, **Stapleton JT**. Hepatitis A through G. *Medical and Health Annual*. Encyclopaedia Britannica, Inc., Bernstein E, ed., pp 235-239, 1997.
59. Schmidt WN, Wu P, Han, JQ, Perino MJ, LaBrecque DR, **Stapleton JT**. Distribution of Hepatitis C Virus (HCV) RNA in whole blood and blood cell fractions: Plasma HCV RNA analysis underestimates circulating viral load. *J Infect Dis.* 176:20-27, 1997.
60. Schmidt WN, Wu P, Cederna J, Mitros FA, LaBrecque DL, **Stapleton JT**. Surreptitious Hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. *J Infect Dis.* 176:27-33, 1997.
61. Han J-Q, **Stapleton JT**. Assay of amino acid mutagenesis in hepatitis A virus cellular receptor binding region. *Virologica Sinica* 12:239-243, 1997.
62. Han J-Q, Schmidt WN, Wu P, Loh P-M, Neil G, LaBrecque DR, **Stapleton JT**. Specific binding of hepatitis C virus to the Fc fragment of IgG molecules. *Virologica Sinica* 12:244-247, 1997.
63. Cook,RT, **Stapleton JT**, Fein G, Shearer GM. Symposium: Alcohol and Human Immunodeficiency Virus Infection. *Alcoholism Clin Exp Res.* 20(supplement 8):210A-215A. 1997.
64. Li F, Cook RT, Rasmussen W, **Stapleton JT**, Ballas Zk. Ethanol and natural killer cells. II. Stimulation of human natural killer activity by ethanol in vitro. *Alcoholism Clin Exp Res.* 21:981-987, 1997.
65. Cook R, **Stapleton JT**, Ballas Z, Klinzman D. Effects of a single ethanol exposure on HIV replication in human lymphocytes. *J Investig Med.* 45:265-271, 1997.
66. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA, and the AIDS Clinical Trials Group 320 Study Team (including **Stapleton JT**) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. *N Engl J Med.* 337:725-733. 1997
67. Wünschmann S, Vallbracht A, Flehmig B, Winokur P, Klinzman D, **Stapleton JT**. Cytolytic T lymphocyte epitopes are present on hepatitis A virus structural proteins. In: *Viral Hepatitis and Liver Disease*, eds. Rizzetto M, Purcell RH, Gerin JL, and Verme G. Edizioni Minerva Medica. Turin. pp. 51-54, 1997.
68. Han J-Q, Schmit WN, Wu P, Loh P, Neil G, LaBrecque DR, **Stapleton JT**. Specific binding of hepatitis C virus to the Fc fragment of immunoglobulin molecules. In: *Viral Hepatitis and Liver Disease*, eds. Rizzetto M, Purcell RH, Gerin JL, and Verme G. Edizioni Minerva Medica. Turin. pp. 228-231, 1997.
69. Lemon SM, **Stapleton JT**. Hepatitis A Virus: Prevention. In: Viral Hepatitis, Zuckerman AJ, Thomas HC, eds. 2nd Edition, Churchill Livingstone, Edinburgh, p. 63-76, 1998.
70. LaBrecque FD, LaBrecque DR, Klinzman D, Perlman S, Cederna JB, Winokur PL, Han J-Q, **Stapleton JT**. Recombinant Hepatitis A Virus Antigen: Improved Production and Utility in Diagnostic Immunoassays. *J Clin Microbiol.* 36:2014-2018, 1998.
71. **Stapleton JT**, Han J-Q, Schmidt WN, and LaBrecque DR. Hepatitis C Virus Fc Binding Domain. United States Patent No. 5,846,735, 1998.

72. Fineberg JE, Hurwitz Sh, Cooper D, Sattler FR, MacGregor RR, Powderly W, Holland GN, Griffiths PD, Pollard RB, Youle M, Gill MJ, Holland FJ, Power ME, Owens S, Coakley D, Fry J, Jacobson MA, and the AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group (including **Stapleton JT**). A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. *J. Infect. Dis.* 177:48-56, 1998.
73. Shutt DC, Jenkins LM, Carolan EJ, **Stapleton J**, Daniels KJ, Kennedy RC, Soll DR. T cell syncytia induced by HIV release T cell chemoattractants: demonstration with a newly developed single cell chemotaxis chamber. *J Cell Sci.*, 111:99-109, 1998.
74. Xiang, JH, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish R, **Stapleton JT**. Characterization of Hepatitis G Virus (GB-C Virus) Particles: Evidence for a Nucleocapsid and Expression of Sequences Upstream of the E1 Protein. *J Virol.* 72:2738-2744, 1998.
75. Schmidt WN, Wu P, Brashear D, Klinzman D, Perino-Phillips MJ, LaBrecque DR, **Stapleton JT**. Effect of Interferon therapy on hepatitis C virus in RNA Whole Blood, Plasma and Peripheral Blood Mononuclear Cells. *Hepatology* 28:1110-1116, 1998.
76. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JPA, Holohan MK, Leavitt R, Goone G, Richman DD and the AIDS Clinical Trials Group Study 343 Team (including **Stapleton JT**). Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. *N Engl J Med* 339:1261-8, 1998.
77. Noormohamed SE, Katseres JK, **Stapleton JT**. Poor correlation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. *Renal Failure* 20: 20:627-633, 1998.
78. Xiang J, Daniels KJ, Soll DR, Schmidt WN, LaBrecque DR, **Stapleton JT**. Visualization and Characterization of GB Virus – C Particles: Evidence for a Nucleocapsid. *J. Viral Hep.* 6:S16-22, 1999.
79. **Stapleton JT**. Hepatitis A: Biology, Pathogenesis, Epidemiology, Clinical Description, and Diagnosis. In: Viral Hepatitis: Diagnosis, Therapy and Prevention. Steven Spector, ed., Humana Press, Totowa, NJ. pp.7-33, 1999.
80. Xiang, JH, **Stapleton JT**. Hepatitis A. *Manual of Clinical Microbiology*, Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover FC, eds., 7th ed., ASM Press, Washington, DC, pp.1014-1024, 1999.
81. Herman RA, Noormohamed S, Hirankarn S, Shelton, Huang E, Gene D. Morse GD, Hewitt RG, **Stapleton JT**. Comparison of a Neural Network Approach with Five Traditional Methods for Creatinine Clearance Prediction in Patients with Human Immunodeficiency Virus Infection. *Pharmacotherapy*, 19:734-740, 1999.
82. El-Sadr WM, Murphy RL, Yurik TM, Luskin-Hawk R, Cheung TW, Balfour HH, Eng R, Hooton TM, Kerkering TM, Schutz M, van der Horst C, Hafner R and the Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group (including **Stapleton JT**). Atovaquone compared with dapsone for the prevention of *Pneumocystis carinii* pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. *N Engl J Med.* 339:1889-1895, 1999.
83. George S, **Stapleton JT**. Status of Viral Hepatitis Vaccines. *Clinical Microbiology Newsletter. Clinical Microbiology Newsletter* 21:113-118, 1999.

84. George SL, Swindells S, Knudson R, **Stapleton JT**. Unexplained Thrombosis in HIV Infected Patients Receiving Protease Inhibitors: Report of Seven Cases. *Am. J. Med.* 107:624-630, 1999
85. **Stapleton JT**, Klinzman D, Schmidt WN, Pfaller MA, Wu P, LaBrecque DR, Han J-Q, Perino-Phillips MJ, Woolson R, Alden B. Prospective Comparison of Whole Blood- and Plasma-Based Hepatitis C Virus RNA Detection Systems: Improved Detection Using Whole Blood as the Source of Viral RNA. *J. Clin. Micro.* 37:484-489, 1999.
86. Cederna, JB, Klinzman D, **Stapleton, JT**. Hepatitis A virus-specific humoral and cellular immune responses following immunization with a formalin-inactivated hepatitis A vaccine. *Vaccine*, 18:892-898, 2000.
87. Schmidt WN, **Stapleton JT**, LaBrecque DR, Mitros FA, Kirby PA, Phillips MJ, Brashear DL. Hepatitis C virus (HCV) infection and cryoglobulinemia: Analysis of whole blood and plasma HCV-RNA concentrations and correlation with liver histology. *Hepatology* 31:737-744, 2000.
88. Wünschmann S and **Stapleton JT**. Fluorescence-based quantitative methods for detecting Human Immunodeficiency Virus Type 1-induced syncytia. *J Clin Micro.* 38:3055-3060, 2000.
89. Xiang J, Wünschmann S, Schmidt WN, Shao J, **Stapleton JT**. Full-length GB virus C (Hepatitis G Virus) RNA transcripts are infectious in primary CD4 positive T cells. *J. Virol.* 74:9125-9133, 2000.
90. Wünschmann S, Medh J, Klinzman D, Schmidt WN, **Stapleton JT**. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low density lipoprotein receptor. *J. Virol.* 74:10055-10062, 2000.
91. Vargas K, Messer SA, Pfaller M, Lockhart S, **Stapleton JT**, Hellstein J, Soll DR. Elevated switching and drug resistance of *Candida* from HIV-Positive individuals prior to thrush. *J. Clin. Micro.* 38:3595-3607, 2000.
92. Xiang J, Wuenschmann S, Diekema D, Klinzman DJ, Patrick KD, George SL, **Stapleton JT**. Effect of CoInfection with GB Virus C on Survival Among Patients with HIV Infection. *N.Engl.J.Med.* 345:707-714, 2001.
93. Schmidt WN, **Stapleton JT**. Whole-Blood Hepatitis C Virus RNA Extraction Methods (letter). *J. Clin. Micro.* 39:3812, 2001.
94. **Stapleton JT**. GB Virus C Delays Mortality in HIV-Infected Individuals. *Biomedicine & Pharmacotherapy.* 56:111-113. 2002.
95. George S, Klinzman D, Schmidt WN, Patrick K, Alden B, Pfaller MA, **Stapleton JT**. Antibody negative HCV infection in HIV positive individuals. In: Viral Hepatitis and Liver Disease. Margolis HS, Alter MJ, Liang TJ, Dienstag JL eds., International Medical Press. London, p 357-361, 2002.
96. Xiang J, Wünschmann S, Schmidt WN, Shao J, **Stapleton JT**. In vitro replication of a GB Virus C infectious clone. In: Viral Hepatitis and Liver Disease. Margolis HS, Alter MJ, Liang TJ, Dienstag JL eds., International Medical Press. London, p 464-468, 2002.
97. **Stapleton JT**, Diekema DJ, Xiang J. GB virus C and mortality from HIV infection. (letter) *N.Engl.J.Med.* 346:378. 2002.
98. **Stapleton JT**, Xiang J, George S, Klinzman D. Evidence for delayed human immunodeficiency virus (HIV) disease progression in HIV-GB virus C co-infected individuals. In: Viral Hepatitis and Liver Disease. Margolis HS, Alter MJ, Liang TJ, Dienstag JL eds., International Medical Press. London, p 469-472, 2002.

99. Ullrich PM, Lutgendorf SK, **Stapleton, J.** Social constraints and depression in HIV infection: Effects of sexual orientation and area of residence. *Journal of Social and Clinical Psychology* 211:47-66. 2002.
100. Kresina TF, Flexner CW, Sinclair J, Correia MA, **Stapleton JT**, Adeniyi-Jones S, Cargill V, Cheever LW. Alcohol Use and HIV Pharmacotherapy. *AIDS Res. Hum. Retro.* 18:757-770, 2002.
101. Xiang J, Wünschmann S, Schmidt WN, George S, Schmidt WN, LaBrecque DR, **Stapleton JT.** Recombinant hepatitis C virus-like particles expressed by baculovirus: Utility in cell-binding and antibody detection assays. *J.Med.Virol.* 68:537-543, 2002.
102. George SL, Gephardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, Alden B, Pfaller MA, **Stapleton JT.** Hepatitis C virus (HCV) viremia in HIV-infected individuals with negative HCV antibody tests. *J. Acquir. Immune Defic. Syndr.* 31:154-162, 2002.
103. George SL, Wünschmann S, McCoy J, Xiang J, **Stapleton JT.** Interactions between GB Virus type C (also known as hepatitis G virus) and HIV. *Current Infectious Disease Reports* 4:550-558, 2002.
104. Brown EA and **Stapleton JT.** Hepatitis A. *Manual of Clinical Microbiology*, Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover BC, eds., 8th ed., ASM Press, Washington, DC, p. 1452-1463, 2003.
105. Ullrich PM, Lutgendorf SK, **Stapleton JT.** Concealment of homosexual identity, social support and CD4 cell count among HIV-seropositive gay men. *J Psychosomatic Res.* 54:205-212, 2003.
106. Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Srtizler J, Kalams SA, Pollard RB, Fahey J, Fox L, Namkung A, Estep S, Moss R, Sahner D, Lederman MM. Interleukin-2 increases CD4+ lymphocyte numbers but does not enhance responses to immunization: Results of A5046s. *J Infect Dis* 187:320-325, 2003. (**Stapleton JT** acknowledged for UI contribution).
107. **Stapleton JT.** Hepatic and Pancreatic Diseases in HIV Infection. In: Approach Towards Management of Human Immunodeficiency Virus Infection and Its Related Complications. Singh N, Shafer RW, and Swindells S, eds., ESUN Technologies, Pittsburgh. Online Text at: www.antimicrobe.org. 2003. Condensed chapter in HIV Clinical Manual, pp. 181 – 213, 2003.
108. **Stapleton JT.** GB Virus type C/Hepatitis G Virus. *Seminars in Liver Disease.* 23:137-148. 2003.
109. Polgreen PM, Putz D, **Stapleton JT.** Inaccurate glycosylated hemoglobin A1C measurements in HIV-positive patients with diabetes mellitus. *Clin Infect. Dis.* 37:e53-56, 2003.
110. Polgreen P, Xiang J, **Stapleton JT.** GB Virus C – HIV Co-Infection. *Microbes and Infection.* 5:1255-1261, 2003.
111. George S, Xiang J, **Stapleton JT.** Clinical isolates of GB virus type C vary in their ability to persist and replicate in peripheral blood mononuclear cell cultures. *Virology.* 316:191-201, 2003.
112. Williams CF, Klinzman D, Yamashita T, Xiang J, Polgreen PM, Rinaldo C, Liu C, Phair J, Margolick JB, Zdunek D, Hess G, **Stapleton JT.** Persistent GB virus C infection and survival in HIV-infected men. *N.Engl.J.Med.,* 350:981-990, 2004.

113. Kim SJ, Jang MH, **Stapleton JT**, Yoon SO, Jeon ES, and Hong HJ. Neutralizing Human Monoclonal Antibodies to Hepatitis A Virus Recovered by Phage Display. *Virology*. 318:598-607, 2004.
114. **Stapleton JT**, Williams CF, Xiang J. GB Virus C: A beneficial infection? *J.Clin.Micro.* 42:3915-3919, 2004.
115. Klinzman D, Katz L, George SL, Chang Q, Xiang J, Zdunek D, Hess G, Schmidt WN, LaBrecque DR, **Stapleton JT**. GB virus C/hepatitis G virus: Does clearance of viremia differ based on mode of transmission? In: 11th:International Symposium on Viral Hepatitis and Liver Disease, p 488-90. Jilbert AR, Grgacic EVL, Vickery K, Burrl CJ, Cossart EE, eds. Australian Center for Hepatitis Virology, publisher. Melbourne, 2004.
116. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, **Stapleton JT**. . GB virus C/hepatitis G virus: In vivo and in vitro beneficial interactions with HIV. In: 11th:International Symposium on Viral Hepatitis and Liver Disease, p 494-496. Jilbert AR, Grgacic EVL, Vickery K, Burrl CJ, Cossart EE, eds. Australian Center for Hepatitis Virology, publisher. Melbourne, 2004.
117. Polgreen PM, Fultz SL, Justice AC, Wagner JH, Diekema DJ, Rabeneck L, Weissman S, **Stapleton JT**. Association of Hypocholesterolemia With Hepatitis C Virus Infection in HIV Infected People. *HIV Med.* 5:144-150, 2004.
118. Ullrich PM, Lutgendorf SK, **Stapleton JT**, Horowitz M. Self Regard and Concealment of Homosexuality as Predictors of CD4+ Cell Count Over Time Among HIV Seropositive Gay Men. *Psychology & Health.* 19:183-196, 2004.
119. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, **Stapleton JT**. GB virus C infection inhibits HIV-1 replication by increasing RANTES, MIP-1 α , MIP-1 β , and SDF-1. *Lancet*, 363:2040-2046, 2004.
120. Weintraub A, Hamilton JD, Hahn C, Klinzman D, Moyo G, Zdunek D, Hess G, Benjamin DK, **Stapleton JT**. Active or Prior GB Virus C Infection Does Not Protect Against Vertical Transmission of HIV in Co-Infected Women from Tanzania. *Clin. Infect. Dis.* 38:e46-48, 2004.
121. **Stapleton JT**, Schmidt WN, Katz L. Seronegative hepatitis C virus infection, not just RNA detection. *J Infect Dis.* 190:651-652, 2004.
122. **Stapleton JT**, Williams CF, Xiang J. GB virus C and HIV interactions (letter). *N.Engl.J.Med.*, 350:2618,2004, 2004.
123. Talbot TR, **Stapleton JT**, Brady RC, Winokur PL, Bernsteing DI, Germanson T, Yoder SM, Rock MT, Crowe JR. JE, Edwards KM. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: A randomized controlled trial. *JAMA* 292:1205-1212, 2004.
124. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, and AIDS Clinical Trials Group A5071 Study Team (including **Stapleton JT**). Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. *N.Engl.J.Med.*, 351:451-459, 2004.
125. **Stapleton JT**, Chaloner K. GB Virus C and survival in HIV-positive people. *AIDS.* 18:2343-2344, 2004.
126. **Stapleton JT**, Xiang J, Wuenschmann S, and Schmidt WN. United States Patent No. 6,870,043 Full-length GB virus C (Hepatitis G Virus) RNA transcripts are infectious in primary CD4 Positive T cells and Methods of treating HIV. 2005.

127. Xiang J, Martinez-Smith C, Gale Jr. M, Chang Q, LaBrecque DR, Schmidt WN, **Stapleton JT**. GB Virus type C NS5A sequence polymorphisms: Association with interferon susceptibility and inhibition of PKR-mediated eIF-2 α phosphorylation. *J Interferon Cytokine Res*, 25:261-270, 2005.
128. **Stapleton JT**, Chaloner K, Williams CF. GB virus C and survival in the Amsterdam Cohort Study. *J Infect Dis*. 191:2157-2158. 2005.
129. **Stapleton, JT**. GBV-C Coinfection and prolonged survival in HIV: The questions persist (editorial). *Clinical Care Options: HIV*. Online journal, May 25, 2005.
130. Schuval S, Lindsey JC, **Stapleton JT**, Van Dyke RB, Palumbo P, Mofenson LM, Oleske JM, Cervia J, Kovacs A, Dankner WN, Smith E, Nowak B, Ciupak G, Webb N, Eagle M, Smith D, Hennessey R, Goodman-Kerkau M, Klinzman D, Hess G, Zdunek D, Levin MJ; the Pediatric AIDS Clinical Trials Group Protocol 1028S Team. GB Virus C Infection in Children With Perinatal Human Immunodeficiency Virus Infection. *Pediatr Infect Dis J*. 24:417-422, 2005.
131. Bisson G, Strom B, Gross R, Weissman D, Klinzman D, Hwang W-T, Kostman J, Hess G, Zdunek D, Metzger D, **Stapleton JT**, Frank I. Effect of GB virus C viremia on HIV acquisition and HIV set-point. *AIDS*. 19:1910-1912, 2005.
132. Xiang J, Sathar MA, McLinden J, Klinzman D, Chang Q, **Stapleton JT**. South African GB virus C isolates: Interactions between genotypes 1 and 5 GBV-C isolates and the human immunodeficiency virus. *J. Infect. Dis*. 192:2147-2151, 2005.
133. Souza IE, Zhang W, Diaz RS, Chaloner K, Klinzman D, **Stapleton JT**. Effect of GB Virus C on response to antiretroviral therapy in HIV infected Brazilians. *HIV Med* 7:25-31, 2006.
134. Zhang W, Chaloner K, Tillmann HL, Williams CF, **Stapleton JT**. Effect of early and late GBV-C viremia on survival of HIV infected individuals: a meta-analysis. *HIV Med*, 7:173-180, 2006.
135. George SL, Varmaz D, **Stapleton JT**. GB virus C replicates in primary T and B lymphocytes. *J. Infect. Dis*. 193:451-454, 2006.
136. Souza IE, Allen JB, Xiang J, Klinzman D, Diaz R, Zhang S, Chaloner K, Zdunek D, Hess G, Williams CF, Benning L, **Stapleton JT**. Optimal testing for GB Virus C viremia: Effect of primer selection on estimates of GBV-C prevalence and response to antiretroviral therapy. *J. Clin. Microbiol*. 44:3105-3113, 2006.
137. **Stapleton JT**, Xiang J, Williams CF. GBV-C and HIV survival (letter). *Lancet Infect. Dis*. 6:187, 2006.
138. Wünschmann S, Müller HM, Stipp CS, Hemler ME, **Stapleton JT**. *In Vitro* interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs. *J. Infect. Dis*. 194:1058-1067, 2006.
139. Xiang J, McLinden JH, Chang Q, Kaufman TM, **Stapleton JT**. An 85 amino acid segment of the GB Virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T-cells. *Proc Natl Acad Sci USA*, 103:15570-15575, 2006.
140. Johannsson, B and **Stapleton JT**. Bacterial and Miscellaneous Infections of the Liver. In: Zakim Boyer Hepatology: A textbook of Liver Disease, Chapter 37, 5th ed. Boyer T, Wright T, and Manns M, Eds. 2006.
141. McLinden JH, Kaufman TM, Xiang J, Chang Q, Klinzman D, Engel AM, Hess G, Schmidt U, Houghton M, **Stapleton JT**. Characterization of an immunodominant antigenic site on GB virus C glycoprotein E2 that is involved in cell binding. *J Virol*, 80:12131-12140. 2006.

142. Kayali Z, Tan S, Shinkunas L, Voigt M, LaBrecque DR, **Stapleton JT**, Brown KE, Schmidt WN. Risk Factors for Hepatitis C Fibrosis: A Prospective study of United States Veterans compared to Non-veterans. *J Viral Hep*, 14:11-21, 2007.
143. Chamie G, Bonacini M, Bangsberg DR, **Stapleton JT**, Hall C, Overton ET, Scherzer R, Tien PC. Factors associated with seronegative chronic hepatitis C virus infection in HIV-infection. *Clin Infect Dis* 44:577-583, 2007.
144. Couch RB, Winokur P, Edwards KM, Black S, Atmar RL, **Stapleton JT**, Kissner JM, Shinefield H, Denny TM, Michael J. Bybel, Newman FK, Yan L. Reducing the Dose of Smallpox Vaccine Reduces Vaccine-Associated Morbidity Without Reducing Vaccination Success Rates or Immune Responses. *J Infect Dis*. 195:826-832, 2007.
145. Dillon DMB, **Stapleton JT**. Selenium effects on HIV RNA and CD4 Cell Counts. *Arch Intern Med*. 167:1556-1557 2007.
146. Kaufman TM, McLinden JH, Xiang J, Engel AM, **Stapleton JT**. The GBV-C envelope glycoprotein E2 does not interact specifically with CD81. *AIDS* 21:10451048, 2007.
147. Future II Study Group (including **Stapleton J**). Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. *N Engl J Med* 356:1915-1927, 2007.
148. Handelsman E, Cheng I, Thompson B, Hershov R, Mofenson LM, Hollinger FB, Chen KT, Burchett SK, Klinzman D, **Stapleton JT** and the Women and Infants Transmission Study Group (WITS). Impact of GB Virus type C Infection on Mother-to-Child HIV Transmission in the Women and Infants Transmission Study Cohort. *HIV Medicine*, 8:561-567. 2007.
149. **Stapleton JT**, Xiang J, George SL. United States Patent No. 7,291,723 GB virus C and methods of treating viral infections. 2007.
150. Scherer CA, Magness CL, Steiger KV, Poitinger ND, Caputo CM, Miner DG, Winokur PL, Klinzman D, McKee J, Pilar C, Ward PA, Gillham MH, Haulman NJ, **Stapleton JT**, Iadonato SP. Distinct Gene Expression Profiles in Peripheral Blood Mononuclear Cells from Patients Infected with Vaccinia Virus, Yellow Fever 17D Virus, or Community Acquired Upper Respiratory Infections. *Vaccine* 25:6458-73, 2007.
151. Chang Q, McLinden JH, **Stapleton JT**, Sathar AM, Xiang J. GB Virus C NS5A protein from genotypes 1, 2, 3, and 5 and a 30 amino acid NS5A fragment expression inhibit HIV-1 replication in a CD4+ T-lymphocytes. *J Gen Virol* 88:3341-3346, 2007.
152. **Stapleton JT**, Bennett K, Bosch RJ, Polgreen PM, Swindells S. Effect of antiretroviral therapy and hepatitis C coinfection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. *HIV Clin Trials*, 8:429-436, 2007.
153. **Stapleton J**. A new variable influencing HCV-related liver disease in HIV-HCV co-infected individuals? *Gastroenterology*, 133:2042-2045, 2007.
154. Zhang W, Chaloner K, Cowles MK, Zhang Y, **Stapleton JT**. A Bayesian analysis of doubly censored data using a hierarchical Cox model. *Stat Med* 27:529-542, 2008.
155. Graziano F, Kettoola S, Munshower J, **Stapleton JT**, Towfic G. Effect of spatial distribution of T-cells and HIV load on HIV progression. *Bioinformatics*. 24:855-860, 2008.
156. Xiang J, McLinden JH, Chang Q, Jordan EL, **Stapleton JT**. Characterization of a peptide domain within the GB virus C NS5A phosphoprotein that inhibits HIV replication, *PLoS One*. 3:e2580 (p. 1-10), 2008.

157. McLinden JH, **Stapleton JT**, Chang Q, Xiang J. Expression of the dengue virus type 2 NS5 protein in a CD4+ T cell line inhibits HIV replication. *J Infect Dis.* 198:860-863, 2008.
158. **Stapleton JT**, Balfour HH, Jr. Coinfection alters the playing field: herpesviruses induce acyclovir to inhibit HIV. *Cell: Host and Microbe.* 4:194-195. 2008.
159. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H, for the MOTIVATE Study Teams (including **Stapleton JT**). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. *N Engl J Med* 359:1429-1441, 2008.
160. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams (Including **Stapleton JT**). Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med* 359:1442-1455, 2008
161. Blankson JN, Klinzman D, Astemborski J, Thomas DL, Kirk GD, **Stapleton JT**. Low frequency of GB virus C viremia in a cohort of HIV-1 infected elite suppressors. *AIDS.* 22:2398-2400, 2008.
162. Zhang W, Zhang Y, Chaloner K, **Stapleton JT**. Imputation Methods for Doubly Censored HIV Data. *J. Stat. Comp. Sim.*, 79:1245-1257. 2009.
163. Mohr EJ, **Stapleton JT**. GB virus type C interactions with HIV: The role of envelope glycoproteins. *J Viral Hep*, 16:757-768. 2009.
164. **Stapleton JT**, Chaloner K, Zhang J, Klinzman D, Souza IE, Xiang J, Landay A, Fahey J, Pollard R, Mitsuyasu R. **GB** virus C viremia is associated with reduced CD4 expansion following interleukin 2 therapy in HIV-infected people receiving HAART. *AIDS* 23:605-610, 2009.
165. **Stapleton JT**. Comment on: GBV-C infection: a silent anti-HIV panacea within? *Trans R Soc Trop Med Hyg.* 103:1291-1292, 2009.
166. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow S-N, Apter D, Kitchener H, Costellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Djenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, for the HPV PATRICIA Study Group (including **Stapleton J**). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. *Lancet.* 374:301-314, 2009.
167. Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Geiseler J, Daar ES, ACTG Study 5202 Team (Including **Stapleton JT**). Abacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy. *N Engl J Med* 361:2230-2240, 2009.
168. Xiang J, McLinden JH, Rydze RA, Chang Q, Kaufman TM, Klinzman D, **Stapleton JT**. Viruses within the *Flaviviridae* decrease CD4 expression and inhibit HIV replication in human CD4+ cells. *J Immunol*, 183:7860-9. 2009.
169. Zhang S, Zhang Y, Chaloner K, **Stapleton JT**. A Copula model for bivariate hybrid censored survival data with application to an HIV study. *Lifetime Data Analysis.* 16:231-249, 2010. (Epub 2009).

170. **Stapleton JT**, Chaloner K. GB Virus C infection and non-Hodgkin lymphoma: Important to know but the jury is out (editorial). *Int J Cancer*, 126:2759-2761, 2010.
171. The International HIV Controllers Study (including **Stapleton JT**). The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. *Science*, 330:1551-1557, 2010.
172. Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV Controllers Study (including **Stapleton JT**), Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH, Montgomery GW, Martin NG. Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. *Am J Hum Genet*, 86:88-92, 2010. (Epub 2009).
173. Mohr EL*, Xiang J*, McLinden JH, Kaufman TM, Chang Q, Montefiori DC, Klinzman D, **Stapleton JT**. GB Virus C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. *J Immunol*, 185:4496-4505, 2010.
174. Hammer SM, Ribaud H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE, AIDS Clinical Trials Group (ACTG) 372A Study Team (including **Stapleton J**). A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. *HIV Clin Trials*. 11:312-324, 2010.
175. Mohr EL, Murthy KK, McLinden JH, Xiang J, **Stapleton JT**. The natural history of nonhuman GB Virus C in captive chimpanzees. *J Gen Virol*, 92:91-100, 2011.
176. **Stapleton JT**, Fong S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: A Review and proposed re-classification as Pegiviruses. *J Gen Virol*, 92:233-246, 2011.
177. Boodram B, Hershov RC, Klinzman D, **Stapleton JT**. GB virus C infection among young, HIV-negative injection drug users with and without hepatitis C virus infection. *J Viral Hep*, 18:3153-159, 2011.
178. Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC; AIDS Clinical Trials Group Study A5202 Team (Including **Stapleton JT**). Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. *Ann Int Med*, 154:445-456, 2011.
179. **Stapleton JT**, Xiang J, Chang Q, McLinden JH. United States Patent No. 7,951,531. Flavivirus NS5A proteins for the treatment of HIV. 2011
180. Goldblatt D, Plikaytis BD, Akkoyunlu M, Antonello J, Ashton L, Blake M, Burton R, Care R, Durant N, Feavers I, Fernsten P, Fievet F, Giardina P, Jansen K, Katz L, Kierstead L, Lee L, Maisonneuve J, Nahm M, Raab J, Romero-Steiner S, Rose C, Schmidt D, **Stapleton JT**, Carlone GM. Establishment of a new Human Pneumococcal Standard Reference serum 007sp. *Clin Vaccine Immunol*, 18:1728-1736, 2011.
181. Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA, and AIDS Clinical Trials Group Study A5202 Team (including **Stapleton JT**). Abacavir/Lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. *J Infect Dis* 204:1191-1201, 2011.

182. **Stapleton JT**, Smith DB, Simmonds P. Evidence against GB virus C infection in dromedary camels. *Vet Microbiol* (Epub 2011), 154:403-406, 2012.
183. Szarewski A, Poppe WA, Skinner SR, **Wheeler CM**, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; for the HPV PATRICIA Study Group (including **Stapleton J**). Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. *Int J Cancer* (Epub, 2011), 131:106-116, 2012.
184. Belshe RB, Leonse PA, Bernstein DI, Wald A, Levin MJ, **Stapleton JT**, Gorfinkel I, Ashley Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD, and the Herpevac Trial for Women. Type specific efficacy of herpes simplex virus type 2 glycoprotein D subunit vaccine: Results of the Herpevac Trial for Women. *N Engl J Med*, 366:34-43, 2012.
185. Vahidnia F, Petersen M, Rutherford G, Busch M, Assmann S, **Stapleton JT**, Custer B. Transmission of GB Virus type C (HGV) via transfusion in a cohort of HIV-infected patients. *J Infect Dis*, 205:1436-1442, 2012.
186. Won R and **Stapleton JT**. HIV/AIDS. Book Chapter in: *Family Practice Examination & Board Review*. Graber M and Wilbur J, eds. 2012.
187. Bhattarai N and **Stapleton JT**. GB virus C: The Good Boy Virus? *Trends in Microbiol*, 20:123-130, 2012.
188. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G; for the HPV PATRICIA Study Group (Including **Stapleton J**). Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol*. (Epub 2011) 13:89-99, 2012.
189. Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M; for the HPV PATRICIA Study Group (Including **Stapleton J**). Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. *Lancet Oncol*. (Epub 2011) 13:100-110, 2012.
190. Bhattarai N, **Stapleton JT**. Study design may explain discrepancies in GB virus C effects on IFN- γ and IL-2 production and CD38 expression in T lymphocytes. *Mem Inst Oswaldo Cruz*, 107:568-9, 2012.
191. Rydze RT, Xiang J, McLinden JH, **Stapleton JT**. GB virus C infection polarizes T cell cytokine gene expression towards a Th1 cytokine profile via NS5A protein expression. *J Infect Dis*, 206:69-72, 2012.
192. Rydze RT*, Bhattarai N*, **Stapleton JT**. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T cell death. *Antivir Ther*, 17:1271-1279, 2012.

193. Jackson LA, Chen WH, **Stapleton JT**, Dekker CL, Wald A, Brady RC, Edupuganti S, Winokur P, Mulligan MJ, Keyserling HL, Kotloff K, Roupheal N, Noah DL, Hill H, Wolff M. Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given with and without AS03 Adjuvant in Healthy Adults and Senior. *J Infect Dis*, 206:811-820, 2012.
194. Xiang J, McLinden JH, Kaufman TM, Mohr EL, Bhattarai N, Chang Q, **Stapleton JT**. Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication. *Virology*, 430:53-62, 2012.
195. Vahidnia F, **Stapleton JT**, Rutherford GW, Busch M, Custer B, Acquisition of GB virus type C (HGV) and lower mortality in patients with advanced HIV disease. *Clin Infect Dis*, 55:1012-1019, 2012.
196. Bhattarai N, McLinden JH, Xiang J, Kaufman TM, **Stapleton JT**. GB virus C envelope protein E2 inhibits T cell receptor induced IL-2 production and alters IL-2 signaling pathways. *J Immunol* 189:2211-2216, 2012.
197. Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL; Pandemic H1N1 Vaccine Adult Study Group (**including Stapleton JT**). Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. *Vaccine*. 30:4240-4248, 2012.
198. Bhattarai N, Rydze RT, Chivero C, **Stapleton JT**. GBV-C viremia is associated with higher levels of double negative T cells and lower T cell activation in HIV-infected individuals on antiretroviral therapy. *J Infect Dis* 206:1469-1472, 2012.
199. McLaren PJ, Ripke S, Pelak K, Weintrob AC, Patsopoulos NA, Jia X, Erlich RL, Lennon NJ, Kadie CM, Heckerman D, Gupta N, Haas DW, Deeks SG, Pereyra F, Walker BD, de Bakker PI; International HIV Controllers Study (**including Stapleton JT**). Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. *Hum Mol Genet*. 21:4334-47, 2012.
200. Bahmanyar ER, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Jaisamrarn U, Limson GA, Garland SM, Szarewski A, Romanowski B, Aoki F, Schwarz TF, Peppe WAJ, de Carvalho NS, Harper DM, Bosch FX, Raillard A, Descamps D, Struyf F, Lehtinen M, Dubin G for the HPV PATRICIA Study Group (**including Stapleton JT**). Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. *Gynecol Oncol* 127:440-450, 2012.
201. **Stapleton JT**, Chaloner K, Martinson JA, Zhang J, Klinzman D, Wallace W, Desai S, Landay AL. GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. *PLoS One*, 7:350563 pages 1-9, 2012.
202. McLinden JH, **Stapleton JT**, Klinzman D, Murthy KK, Chang Q, Kaufman TM, Xiang J. Chimpanzee GB virus C (GBV-Ccpz) and GB virus A (GBV-A) E2 envelope glycoproteins contain a peptide motif that inhibits HIV replication in human CD4+ T cells. *J Gen Virol*, 94:774-782, 2013.
203. Siewe B, **Stapleton JT**, Martinson J, Kesharvazian A, Kazmi N, Demarais PM, French AL, Landay A. Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8 T cell function *in vitro*. *J Leuk Biol*, 93:811-818, 2013.

204. Bhattarai N, McLinden JH, Xiang J, Landay A, Chivero ET, **Stapleton JT**. GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of T cell receptor signaling. *J Immunol*, 190:6351-6359, 2013.
205. Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsague X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torne A, David MP, Struyf F, Lehtinen M, Dubin G (with PATRICIA Study Team including **Stapleton JT**). Efficacy of the HPV-16/18 ASO4-adjuvanted vaccine against low-risk HPV types (Patricia randomized trial): an unexpected observation. *J Infect Dis*, 208:1301-1396, 2013.
206. **Stapleton JT**, Martinson JA, Klinzman D, Xiang J, Desai SN, Landay A. GB virus C infection and B cell, NK cell and monocyte activation markers in HIV-infected individuals. *AIDS*, 27:1829-1832, 2013.
207. Jaisamrarn U, Castellsague X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmeron J, Chow SN, Apter D, Teixeira JC, Skinner SR, Hedrick J, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, de Carvalho NS, Germar MJ, Peters K, Paavonen J, Bozonnet MC, Descamps D, Struyf F, Rosillon D, Baril L, HPV PATRICIA Study Group including **Stapleton, J**). Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. *PLoS One* 8:e79260, p. 1-15, 2013.
208. Sahni H, Kirkwood K, Kyriakides TC, Stapleton J, Brown ST, Holodniy M for the OPTIMA Study Team. GBV-C viremia and clinical events in advanced HIV infection. *J Med Virol*, 86:426-432, 2014.
209. Zhang J, Chaloner K, McLinden JH, **Stapleton JT**. Bayesian analysis and classification of two Enzyme-Linked Immunosorbent Assay (ELISA) tests without a gold standard. *Stat Med*, 32:4102-4117, 2013
210. Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl, Daar ES, Collier AC, and the AIDS Clinical Trials Group 5202 Study Team (including **Stapleton JT**). Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. *Clin Infect Dis*, Epub November 18, 2013.
211. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, **Stapleton JT**, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 66 subtypes, updated criteria and assignment web resource. *Hepatology*, ePub 2013, 59:318-327, 2014.
212. Siewe B, Wallace J, Rygielski S, **Stapleton JT**, Martin J, Deeks SG, Landay A. Regulatory B cells Inhibit Cytotoxic-competent T Lymphocytes and Elimination of Infected CD4 T cells after ex vivo Reactivation of HIV Latent Reservoirs. *PLoS One*, 9:e92934, 2014.
213. Chivero ET, Bhattarai N, Rydze RT, Winters MA, Holodniy M, **Stapleton JT**. Human Pegivirus (HPgV or GB virus C) RNA is found in multiple blood mononuclear cells *in vivo* and serum-derived viral RNA containing particles are infectious *in vitro*. *J Gen Virol*, 95:1307-1319, 2014.
214. **Stapleton JT**, Xiang J, McLinden JH, Bhattarai N, Chivero ET, Klinzman D, Kaufman TM, Chang Q. A novel T cell evasion mechanism in persistent RNA virus infection. *Trans Am Clin Climatol Assn*. 125:14-26, 2014.

215. Haffizulla J, Hartman A, Hoppers M, Resnick H, Samudrala S, Ginocchio C, Bardin M, Rossignol JF, for the US Nitazoxanide Influenza Clinical Study Group (including **Stapleton J**). Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomized, placebo-controlled, phase 2b/3 trial. *Lancet Inf Dis*, 14:609-618, 2014.
216. Callahan ST, Wolff M, Hill HR, Edwards KM; NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group (including **Stapleton J**). Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. *J. Infect. Dis.* 210:1270-1274, 2014.
217. Chang CM, **Stapleton JT**, Klinzman D, McLinden JH, Purdue MP, Katki HA, Engels EA. GBV-C infection and risk of NHL among U.S. adults. *Cancer Res.* 74:5553-5560, 2014.
218. Castellsague X, Naud P, Chow S-N, Wheeler CM, Germar MJV, Lehtinen M, Paavonen J, Jaisamrarn U, Garland SM, Salmeron J, Apter D, Kitchener H, Teixeira JC, Skinner SR, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch X, de Carvalho NS, Peters K, Tjalma WAA, Safaeian M, Raillard A, Descamps D, Struyf F, Dubin G, Rosillon D, Baril L, (and PATRICIA study group including **Stapleton J**). Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. *J Infect Dis* 210:517-534, 2014.
219. **Stapleton JT**, Xiang J, Klinzman D, McLinden JH. United States Patent No. 8,858,946 “Method for inhibiting HIV-1 replication utilizing anti-GBV-C E2 antibodies”. October 14, 2014
220. Mulligan MJ, Bernstein DI, Winokur P, Rupp R, Lai L, Anderson E, Roupheal N, Dickey M, **Stapleton JT**, Edupuganti S, Spearman P, Kabbani S, Ince D, Noah DL, Hill H, Belamy AR, for the DMID 13-0032 H7N9 Vaccine Study Group. Influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant. A randomized clinical trial of a pandemic threat response. *JAMA*, 312:1409-1419, 2014.
221. Skinner RS, Szarewski A, Romanowski B, Garland SM, Lazcano-Ponce E, Salmerón J, Del Rosario-Raymundo MR, Verheijen RHM, da Silva DP, Kitchener H, Fong KL, Bouchard C, Money DM, Ilancheran A, Cruickshank ME, Levin MJ, Chatterjee A, **Stapleton JT**, Martens M, Quint W, David M-P, Meric D, Hardt K, Descamps D, Geeraerts B, Struyf F, Dubin G, for the VIVIANE Study Group. Efficacy, safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in women over 25 years: 4-year interim follow-up of the double-blind, randomised VIVIANE study. *Lancet*, 384:2213-2227, 2014.
222. Lanteri M, Vahidnia F, Tan S, **Stapleton JT**, Norris PJ, Heitman J, Deng X, Keating S, Brambilla D, Busch MP, Custer B. Down-regulation of cytokines and chemokines by GB virus C after transfusion-transmission in HIV+ blood recipients. *J Infect Dis*, 211:1585-1596, 2015.
223. Chivero ET, **Stapleton JT**. Tropism of human Pegivirus (formerly known as GB virus C/Hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection. *J. Gen. Virol.* 96:1521-1532, 2015.
224. Chivero ET, Bhattarai N, McLinden JH, Xiang J, **Stapleton JT**. Human Pegivirus (HPgV; formerly known as GBV-C) inhibits IL-12 dependent natural killer cell function. *Virology* 485:116-127, 2015.
225. Appenheimer AB and **Stapleton JT**. HIV/AIDS. Book Chapter in: *Family Practice Examination & Board Review*. Graber M and Wilbur J, eds. 2015.

226. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study Group (including **Stapleton J**). A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. *N Engl J Med*, 372:711-723, 2015
227. Keital WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael (NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR, VTEU H3N2v Vaccine Study Work Group (including **Stapleton J**). *J. Infect. Dis.* 212:552-561, 2015.
228. Overton ET, **Stapleton J**, Frank I, Hassler S, Goepfert PA, Barker D, Wagner E, von Krempelhuber A, Virgin G, Meyer TP, Mueller J, Baedeker N, Gruenert R, Young P, Roesch S, Maclennan J, Arndiz-Wiedeman N, Chaplin P. Safety and immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naïve and experienced HIV-infected individuals; An open-label, controlled clinical Phase II trial. *Open Forum Infectious Diseases*, 2:ofv040 eCollection, 2015. PMID 26380340
229. Chastain CA, Beekmann SE, Wallender EK, Hulgán T, **Stapleton JT**, Polgreen PM. Hepatitis C management and the infectious diseases physician: a survey of current and anticipated practice patterns. *Clin Infect Dis*, 61:792-794, 2015.
230. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM for the Costa Rica Vaccine Trial and the PATRICIA study groups (including **Stapleton J**). Efficacy of fewer than three doses of an HPV-16/18 ASO4-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and Patricia Trials. *Lancet Oncol*, 16:775-786, 2015.
231. Longenecker CT, Kitch D, Sax PE, Daar ES, Tierney C, Gupta SK, McComsey GA; AIDS Clinical Trials Group Study A5224s Team (including **Stapleton JT**). Reductions in plasma cystatin C after initiation of antiretroviral therapy are associated with reductions in inflammation: ACTG A5224s. *J Acquir Immune Defic Syndr*, 69:168-177, 2015.
232. Frey SE, Wald A, Edupuganti S, Jackson LA, **Stapleton JT**, El-Sahly SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Chaplin P, Belshe RB, and the DMID 09-0002 MVA Study Group. Comparison of lyophilized versus liquid modified vaccinia Ankara (MV) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. *Vaccine*, 22:5225-5234, 2015.
233. Apter D, Wheeler CM, Paavonen J, Castellsague X, Garland SM, Skinner SR, Naud P, Salmeron J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group (including **Stapleton JT**). Efficacy of human papillomavirus 16 and 18 (HPV-16/18) ASO4-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. *Clin Vaccine Immunol*, 22:361-373, 2015.
234. Dogan MV, Xiang J, Beach S, Cutrona C, Gibbons F, Simons R, Brody G, **Stapleton JT**, Philibert RA. Ethnic and smoking associated DNA methylation changes at HIV co-receptor GPR15. *Front Psychiatry: Molecular Psychiatry*, 6:00132. Doi: 10.3390, 2015.
235. Bhattarai N, McLinden JH, Xiang J, Kaufman TM, **Stapleton JT**. Conserved motifs within hepatitis C virus envelope (E2) protein RNA and protein independently inhibit T cell activation. *PLoS Pathog*, 11: e1005183, p. 1-23, 2015.

236. Zhang JY, Zhang Y, Chaloner K, **Stapleton JT**. A sequential classification rule based on multiple quantitative tests in the absence of a gold standard. *Stat Med*, 35:1359-1372, 2016.
237. Greenberg RN, Hay CM, **Stapleton JT**, Marbury TC, Wagner E, Kreitmeir E, Roesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P. A randomized, double-blind, placebo-controlled Phase II trial investigating the safety and immunogenicity of modified vaccinia Ankara smallpox vaccine (MVA-BN) in 56-80 year-old subjects. *PLoS One*. 11:e0157335, 2016.
238. Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, Garland SM, Chatterjee A, Lazcano-Ponce E, Salmerón J, McNeil S, **Stapleton JT**, Bouchard C, Martens MG, Money DM, Quek SC, Romanowski B, Vallejos CS, Ter Harmsel B, Prilepskaya V, Fong KL, Kitchener H, Minkina G, Lim YK, Stoney T, Chakhtoura N, Cruickshank ME, Savicheva A, da Silva DP, Ferguson M, Molijn AC, Quint WG, Hardt K, Descamps D, Suryakiran PV, Karkada N, Geeraerts B, Dubin G, Struyf F; VIVIANE Study Group. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 ASO4-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomized controlled VIVIANE study. *Lancet Infect Dis*. S1473-3099(16)30120-7. 2016
239. Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff AS, Pletnev A, Rico-Hesse R, **Stapleton JT**, Simmonds P. Proposed update to the taxonomy of the genera *Hepacivirus* and *Pegivirus* within the *Flaviviridae* family. *J Gen Virol*. 97:2894-2907, 2016.
240. Gajurel K, **Stapleton JT**. Hepatitis Viruses in Kidney Transplantation. *Semin Nephrol*. 36:386-396, 2016.
241. Simmonds P, Becher B, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff S, Pletnev A, Rico-Hesse R, Smith DB, **Stapleton JT**, and ICTV Report Consortium. ICTV Virus Taxonomy Profiles: *Flaviviridae*. *J Gen Virol*, 98:2-3, 2017.
242. Bhattarai N, McLinden JH, Xiang J, Mathahs MM, Schmidt WN, Kaufman TM, **Stapleton JT**. Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo. *PLoS Pathogens*, 13:e1006232, 2017.
243. DeLeon O, Hodis H, O' Malley Y, Johnson J, Salimi H, Zhai Y, Winter E, Remec C, Eichelberger N, Van Cleave B, Puliadi R, Harrington R, **Stapleton JT**, Haim H. Accurate Predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled Diffusion Model. *PLoS Biol*, 15:32001549, 2017.

Other:

- 1992 Mini-Sabbatical: 3 months hosted by Bertram Flehmig, M.D., Ph.D., University of Tuebingen. Cell mediated immune responses to recombinant hepatitis A virus particles.
- 1999 Sabbatical: 2 months hosted by Donald Smith, Ph.D., University of Edinburgh, 10 months with David Soll, University of Iowa. Project: HIV coinfection with HCV and/or GB Virus C. Funded by VA Career Development award
- 2008 Sabbatical: University of Edinburgh hosted by Peter Simmonds, Ph.D.

Inventor on U.S. Patents:

- No. 5,294,548: Recombinant Hepatitis A Virus Vaccine. 1994
- No. 5,846,735, "Hepatitis C Virus Fc Binding Domain". 1998
- No. 6,870,043. "Full-length GB virus C (hepatitis G virus) RNA transcripts are infectious in primary CD4 positive T cells". 2005
- No. 7,291,723 "GB virus C and methods of treating viral infections". 2007
- No. 7,951,531 "Flavivirus NS5A proteins for the treatment of HIV". 2011
- No. 8,858,946 "Method for inhibiting HIV-1 utilizing anti-GBV-C E2 antibodies". 2014

Provisional Patent application: *PCT/US2014/027147 based on U.S. Serial No. 61/787,895;*
“Viral Proteins as Immunomodulatory Agents and Vaccine Components” by
Jack T. Stapleton, Nirjal Bhattarai, James H. McLinden, and Jinhua Xiang.”

Provisional Patent application: *PCT/US2014/027147 based on U.S. Serial No. 62/051,727;*
“Viral RNA segments as immunomodulatory agents and vaccine components” by Jack T.
Stapleton, Nirjal Bhattarai, James H. McLinden, and Jinhua Xiang.